Sandra Ammann

Freiburg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Journal: Human gene therapy

Published: July 02, 2026

Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation.

Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation.

Journal: Cell stem cell

Published: August 19, 2025

ERCC6L2 ensures repair fidelity for staggered-end DNA double-strand breaks.

ERCC6L2 ensures repair fidelity for staggered-end DNA double-strand breaks.

Journal: Nature communications

Published: July 16, 2025

Targeted inhibition of ELANE expression using adenine base editing to treat severe congenital neutropenia.

Targeted inhibition of ELANE expression using adenine base editing to treat severe congenital neutropenia.

Journal: Molecular therapy. Methods & clinical development

Published: May 09, 2025

Simultaneous orthogonal cell engineering by a single CRISPR-Cas9 polyfunctional editor.

Simultaneous orthogonal cell engineering by a single CRISPR-Cas9 polyfunctional editor.

Journal: Nature communications

Published: April 28, 2025

Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosa.

Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosa.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 25, 2025

Lipid nanoparticle-based non-viral in situ gene editing of congenital ichthyosis-causing mutations in human skin models.

Lipid nanoparticle-based non-viral in situ gene editing of congenital ichthyosis-causing mutations in human skin models.

Journal: Cell stem cell

Published: April 03, 2025

Base edited skin equivalents with clinical potential for ex vivo correction of recessive dystrophic epidermolysis bullosa.

Base edited skin equivalents with clinical potential for ex vivo correction of recessive dystrophic epidermolysis bullosa.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: March 04, 2025

Syntaxin11 Deficiency Inhibits CRAC Channel Priming To Suppress Cytotoxicity And Gene Expression In FHLH4 Patient T Lymphocytes.

Syntaxin11 Deficiency Inhibits CRAC Channel Priming To Suppress Cytotoxicity And Gene Expression In FHLH4 Patient T Lymphocytes.

Journal: bioRxiv : the preprint server for biology

Published: November 01, 2024

Targeted gene editing and near-universal cDNA insertion of CYBA and CYBB as a treatment for chronic granulomatous disease.

Targeted gene editing and near-universal cDNA insertion of CYBA and CYBB as a treatment for chronic granulomatous disease.

Journal: Nature communications

Published: July 05, 2024

Correction: Patients and mice with deficiency in the SNARE protein SYNTAXIN-11 have a secondary B cell defect.

Correction: Patients and mice with deficiency in the SNARE protein SYNTAXIN-11 have a secondary B cell defect.

Journal: The Journal of experimental medicine

Published: May 21, 2024

Author Correction: IFNγ binding to extracellular matrix prevents fatal systemic toxicity.

Author Correction: IFNγ binding to extracellular matrix prevents fatal systemic toxicity.

Journal: Nature immunology

Published: April 19, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026